FDA Approved: PRIFTIN — Supplemental Application (sanofi-aventis U.S. LLC)

View source ↗

Summary

FDA approved a supplemental application for Priftin (rifapentine) by Sanofi-Aventis U.S. LLC, updating the drug’s labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Latent Tuberculosis Infection
• Tuberculosis

Drugs mentioned

• Priftin (rifapentine)

Snippet

SUPPL AP for PRIFTIN (RIFAPENTINE)